Printer Friendly

ROBERTS PHARMACEUTICAL CORPORATION LAUNCHES SUPPRELIN -- ROBERTS' FIRST NEW DRUG LAUNCH IN THE U.S.

 EATONTOWN, N.J., Dec. 23 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced earlier today that it has successfully launched SUPPRELIN(R), Roberts' first new drug launched in the United States.
 SUPPRELIN is an endocrine drug used to treat Central Precocious Puberty (CPP), a childhood disorder characterized by the abnormally early onset of sexual development associated with puberty. The drug will be promoted to pediatric endocrinologists who specialize in the treatment of this disease.
 SUPPRELIN belongs to a class of drugs known as LHRH superagonists. Roberts has another superagonist under development called SOMAGARD(R) which is in development for CPP as well as for prostate cancer and endometriosis. Roberts is developing a 60 day long-acting formulation of both compounds and expects to market this new formulation after successfully completing clinical trials and obtaining regulatory approval.
 "SUPPRELIN is a safe and effective drug for the treatment of Central Precocious Puberty," noted Dr. Robert A. Vukovich, Roberts' president and CEO. "We are excited by the prospect of this first launch of a new chemical entity drug by Roberts' growing sales force," he continued.
 Roberts Pharmaceutical Corporation is an international pharmaceutical company focusing on the acquisition and development of high-potential, undervalued, late-stage development products and the acquisition of currently marketed prescription and nonprescription products. Roberts products are currently marketed in seven countries with operating subsidiary companies in the United States, Canada, and the United Kingdom. Roberts has seven drugs in late stage clinical development and currently markets over 80 different products for urological therapy, pain management, cough/cold, gastrointestinal disease, endocrine disorders and dermatological conditions.
 -0- 12/23/92
 /CONTACT: Anthony P. Maris of Roberts, 908-389-1182/
 (RPCX)


CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: PDT

GK-LR -- NY016 -- 9523 12/23/92 11:22 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 23, 1992
Words:293
Previous Article:RECOGNITION ANNOUNCES MINISTRY OF TRANSPORTATION ORDER
Next Article:KIRBY CORP. REPORTS RESULTS
Topics:


Related Articles
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES UK APPROVAL FOR SOMAGARD
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES LAUNCH OF NEW U.K. CARDIOVASCULAR DRUG
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES 1994 CORPORATE AWARD FOR ORPHAN DRUG DEVELOPMENT
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES APPROVABLE LETTER AND PREPARES FOR U.S. LAUNCH OF PROAMATINE
Roberts Pharmaceutical Corporation Receives FDA Clearance to Launch ProAmatine, the Company's First Pipeline Drug for the U.S. Market
Roberts Pharmaceutical Corporation Concludes Special Shareholders Meeting and Also Notes FDA Labeling Review of Agrelin in Progress
Roberts Pharmaceutical Corporation Receives FDA Approvable Letter For AGRYLIN Drug Targets A Therapeutic Void
Roberts Pharmaceutical Corporation Announces Priority Review Status in Canada For Its New Drug Agrylin And Plans to File This Year For European...
Roberts Pharmaceutical Corporation Receives Exclusive License from Pfizer Inc. to Develop Novel New Compound for Large Cardiovascular Market
Roberts Pharmaceutical Corporation Receives Canadian Approval For Its New Drug Agrylin

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters